well this is great news & thanks again for sharing your research.
I guess we need to also remember as well there have been 3 large validation studies of PromarkerD since Omics came on board for the Latin American market, 2 with Janssen plus 1 independent in clinical & multiple other lab studies, clinical utility & payor related cost savings (private and Govt), all of which gives evidence & rationale for regulatory approvals & uptake of the test.
It’s all coming together, & just another thing, PASC meeting scheduled 9-10 December for PromarkerD.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)